Pure Global AI
NCT06110663Not yet recruiting

A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

A Phase 3, Randomized, Open-label, Multicenter Study to Assess the Efficacy and Safety of HS-10241 Combined With Almonertinib Versus Pemetrexed Combined With Platinum in Metastatic or Locally Advanced NSCLC With MET Amplification After Failure of the Prior EGFR -TKI Therapy
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-Small Cell Lung Cancer
Drug/Device/Intervention
HS-10241+ Almonertinib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Timeline & enrollment
Phase
Phase 3
Start date
Dec 30, 2023
End date
Feb 28, 2025
Enrollment
314 participants
Primary outcome

Progression-free Survival (PFS) evaluated by Independent Review Committee (IRC)

Summary

HS-10241, an oral and highly selective MET-TKI, may contribute to overcoming common acquired
 MET-based resistance mechanisms following prior EGFR-TKI monotherapy. This study is conducted
 to evaluate the efficacy and safety of HS-10241 combined with Almonertinib versus
 platinum-based chemotherapy in NSCLC with MET amplification after failure of EGFR-TKI
 treatment.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06110663
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06110663 through Pure Global AI's free database. This Phase 3 trial is sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 314 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.